BioSpace News Archive

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has received a Notice of Allowance for its second composition matter patent to be awarded by the Canadian Intellectual Property Office. This ne

WIXOM, Mich., April 20, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced that the Board of Directors has appointed Russell H. Ellison, M.D., M.Sc. as President and Chief Executive Officer, effective immediately. Dr. Ellison will continue to serve as a member of the Company’s Board. Stuart Paul has resi

Tivity Health, Inc. (Nasdaq: TVTY) today announced that its financial results for the first quarter ending March 31, 2020, will be released after market close on Wednesday, May 6, 2020, followed the same day by a conference call and live webcast scheduled for 5:00 p.m. ET.

ELITechGroup MDx LLC, a leading global provider of diagnostic testing products, and its Korean partner, OSANG Healthcare, announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its SARS-CoV-2 virus test for use in the United States .

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the record date for the previously announced distribution to our stockholders of shares of Hoth Therapeutics, Inc. (“Hoth”) is April 30, 2020 , and the Company is currently working to determine the date of distribution.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2020 financial results on Wednesday, April 29, 2020 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). The conference call will be webcast live and a link to the webcast can be accessed through Verte

Alexion Announces Plans to Initiate Phase 3 Study of ULTOMIRIS ® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19 - Global study to enroll approximately 270 adults with COVID-19 and severe pneumonia or acute respiratory distress syndrome - - Company maintains commitment to supplying its medicines to patients for currently approved indications -

nded team will enhance Elanco’s customer focus, expertise and agility as a dedicated animal health company

OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced that its Optoelectronics and Manufacturing division has received an order for approximately $8 million to provide electronic sub-assemblies for a leading healthcare original equipment manufacturer (OEM). OSI Systems’ Chairman and Chief Executive Officer, Deepak Chopra, stated, “We

As previously announced, Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga”) and Aegea Biotechnologies, Inc. (“Aegea”) have entered into a collaboration agreement to develop COVID-19 (Novel Coronavirus) assays. Aegea has now informed Tauriga Sciences that in addition to the high sensitivity, high specificity COVID-19 assay under development (the “SARS-CoV-2 Test”), Aegea is undertaking to use another of its pate